- Open Access
Stromal ING1 expression induces a secretory phenotype and correlates with breast cancer patient survival
© Thakur et al. 2015
- Received: 17 April 2015
- Accepted: 13 August 2015
- Published: 27 August 2015
Previous studies have established that levels of the Inhibitor of Growth 1(ING1) tumor suppressor are reduced in a significant proportion of different cancer types. Here we analyzed levels of ING1 in breast cancer patients to determine its prognostic significance as a biomarker for breast cancer prognosis.
We used automated quantitative analysis (AQUA) to determine the levels of ING1 in the tumor associated stromal cells of 462 breast cancer samples. To better understand how high ING1 levels affect nearby epithelium, we measured the levels of cytokines and secreted matrix metalloproteases (MMPs), using an ELISA based assay in mammary fibroblasts overexpressing ING1. These cells were also used in a 3-dimensional co-culture with MCF7 cells to determine the effect of released MMPs and other cytokines on growing colonies.
We find that high levels of ING1 in stroma are associated with tumor grade (p = 0.001) and size (p = 0.02), and inversely associated with patient survival (p = 0.0001) in luminal, but not in non-luminal cancers, suggesting that high stromal ING1 promotes cancer development. In this group of patients ING1 could also predict patient survival and act as a biomarker (HR = 2.125). While ING1 increased or decreased the expression of different cytokines, ING1 also increased the levels of MMP1, MMP3 and MMP10 by 5–8 fold, and concomitantly decreased levels of the tissue inhibitors of metalloproteases TIMP2, TIMP3 and TIMP4 by 1.5–3.3 fold, resulting in significant increases in MMP activity as determined by zymography. Co-culturing of MCF7 cells with stromal cells expressing ING1 in 3-dimensional organoid cultures suggested that MCF7 colonies were less well defined, suggesting that secreted MMPs might promote migration.
These data indicate that stromal ING1 expression can predict the survival of patients with luminal breast cancer. High levels of ING1 in stromal cells can promote the development of breast cancer through increased expression and release of MMPs and down regulation of TIMPs, which may be an underlying mechanism of reduced patient survival.
- Luminal breast cancer
- Tumor suppressor
Progression of tumors towards a malignant phenotype is not exclusively dependent on the autonomous properties of cancer cells, but is also influenced by the surrounding stroma. Tumor microenvironment which includes the extracellular matrix, surrounding blood vessels, endothelial cells, cancer-associated fibroblasts (CAFs), macrophages and other inflammatory cells, plays an important role in cancer progression. As a cancer progresses, its surrounding microenvironment co-evolves with it and attains an activated state through continuous paracrine communication, which creates a dynamic signaling interaction that promotes cancer initiation and growth .
The most prominent cell types in the tumor stroma are the cancer-associated fibroblasts. CAFs are heterogeneous populations and their relative composition differs among different tumor types . The mechanisms that can activate CAFs in the stroma are still not clearly understood but it is believed that tumor released factors such as tumor growth factor beta (TGF-β), platelet derived growth factor α/β (PDGFA, PDGFB), fibroblast growth factor (FGF) and interleukin-6 (IL-6) play major roles in trans-differentiation and activation of CAFs [3–6]. Activated CAFs are known to contribute to tumor progression by various cellular mechanisms. These cells produce and release several hormones and cytokines such as epidermal growth factors, fibroblast growth factors, IL-6 etc., that can stimulate cancer cells to proliferate rapidly . While CAFs are well characterized for supporting tumor progression, a few studies have also reported their cancer-initiating capacity . In addition to providing growth cues to cancer cells, CAFs also contribute in evading apoptosis by constantly providing them with survival signals like cytokines and insulin like growth factor (IGF) . They are also known to produce various matrix components like collagen, which makes the extracellular membrane (ECM) more cross-linked and has been shown to enhance integrin signaling in cancer cells, which in turn can activate pro-survival PI3K/AKT pathways downstream . CAF secreted cytokines and chemokines also lead to the infiltration of various pro-inflammatory immune cells, which can promote angiogenesis and metastasis . Particularly, CAF released factors such as stromal derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), IL-8, IL-6, and IL-1β cooperate and promote new vessel formation by recruiting endothelial cells .
CAFs also secrete several members of the matrix metalloproteases (MMP) family. These enzymes can degrade ECM, which helps tumor cells invade the surrounding tissues. MMPs can also cleave membrane bound growth factors like VEGF and cytokines as well as their receptors and cell adhesion molecules like cadherins, which can lead to increased motility and result in epithelial to mesenchymal transition (EMT) [13, 14]. As stroma derived factors promote initiation, growth and progression of tumor cells, they can also determine the therapeutic outcome in patients as they can act as barriers to therapy .
Senescence can also affect tissue microenvironment reactivity as well as secreted factors from CAFs. Senescent fibroblasts acquire a senescence-associated secretory phenotype (SASP) which turns senescent fibroblasts into pro-inflammatory cells allowing them to increase their pro-inflammatory and pro-angiogenic cytokine and chemokine production. SASP induction in stromal fibroblasts has been positively correlated with tumor progression and it has been observed that they show this effect by inducing EMT in nearby epithelial cells . Along with various cytokines, senescent cells also secrete increased levels of some MMPs. The MMP family members that are consistently upregulated in senescent fibroblasts are MMP-1, MMP-3 and MMP-10 . These increased levels of secreted MMPs can degrade the components of the extracellular matrix, which can affect the physical property of the tissue structure. This could help tumor cells migrate and invade through the ECM. It has also been observed that senescent cells and malignant tumors share many common repertoires of MMPs indicating the significance of senescence induction in tumor cell metastasis.
All ING family members (ING1-5) have been reported to be altered in localization, sequence, or expression level in various cancer types and are classified as type-II tumor suppressors . The human ING1 gene encodes four different isoforms, p47ING1a, p33ING1b, p24ING1c, and p27ING1d, among which p47ING1a and p33ING1b are the best characterized so far [19, 20]. ING gene products possess distinct, but in some cases overlapping functional properties and unique expression profiles in eukaryotic systems [18, 21]. Ectopic overexpression of ING1 has been found to block cell cycle progression by arresting cells in G1 phase of the cell cycle, and long term expression promotes apoptosis. Particularly, overexpression of p47ING1a is known to induce senescence like characteristics including high SA-β-gal activity, presence of SAHF, altered nuclear morphology, increased expression of p16 and Rb and growth arrest , whereas, p33ING1b overexpression induces cells to undergo apoptosis . Consistent with a role as a tumor suppressor, inhibition of ING1 expression with antisense RNA promotes focus formation in vitro and tumor formation in vivo [24, 25]. Loss of ING1 expression has been implicated in a broad range of human cancer types, including primary breast tumors, lymphoid malignancies, testis tumors, squamous cell cancers, and head and neck cancers [18, 26–28]. Other members of the ING family, and in particular ING4, have also been reported to be down-regulated in breast cancers with a dominant mutant allele of the ING4 gene promoting tumor growth [29, 30]. Recently, we reported that reduced ING1 levels are correlated with increased metastasis in breast cancer patients .
Here we asked if ING1 expression could predict breast cancer patient outcome using an automated quantitative immune-histological technique to determine ING1 expression in the tumoral and stromal compartments of patient tissue samples. We found that stromal expression of ING1 showed an inverse correlation with patient survival. ING1 expression also correlated with tumor grade in these patients and multivariate analysis showed that ING1 was an independent prognostic marker in the breast cancer cohort we tested. Furthermore, we found that ING1 expression can regulate the levels of various cytokines, matrix metalloproteases and their inhibitors, tissue-inhibitors of matrix metalloproteases in mammary fibroblasts that could explain partly, at least, the inverse correlation between the stromal ING1 expression and patient survival. Overall, this study provides important pre-clinical data that could help establish ING1 as a prognostic and therapeutic agent for breast cancer.
Stromal ING1 expression in breast cancer patient samples
Figure 1b middle panel shows a representative image of a sample with low stromal ING1 expression (AQUA score 25.6) and the bottom panel shows representative images of a patient sample with high stromal ING1 expression (AQUA score 291).
Prognostic value of stromal ING1 expression in breast cancer patients
As described previously, the cohort tested in this study has patients classified into luminal breast cancer (ER positive and Her2 negative, n = 430) and non-luminal breast cancer (ER negative or Her2 positive, n = 32) groups for analysis. We tested the prognostic value of stromal ING1 expression in both populations.
Association of clinico-pathological characteristics of ER+/HER2- breast cancer patients with levels of ING1 in the stroma
# of cases (%)
< 2 cm
≥ 2 cm
Lymph node status
Multivariate analysis of disease free survival
9 % CI
Lymph node status
Lymph node status
ING1 regulates levels of cytokines produced in mammary fibroblasts
Functional assay for MMPs regulated by ING1a in HMF3s cells
Since we saw a significant change in the levels of MMPs released by HMF3s cells upon ING1a overexpression, our next question was to determine the functional activity of the MMPs produced. The activation of MMPs is believed to be a key feature in inducing tumor invasiveness and metastasis both in vitro and in vivo and both MMP-1 and MMP-2 have been identified as genes associated with the ability of human breast cancer cells to metastasize spontaneously to the lungs in immune deficient mice . In another study involving a mammary fat pad rat xenograft model, expression of MMP-1 in stromal fibroblasts was shown to confer high invasion potential to breast carcinoma cells .
Using zymography analysis, we determined the caseinolytic and gelatinolytic activity of MMP-1 and MMP-2 respectively in cells expressing ING1a. Results obtained from this experiment were in line with the results from ELISA based analysis as conditioned media from HMF3s cells overexpressing ING1a had greater MMP-1 activity compared to media from untreated cells and GFP only expressing cells (Fig. 4b). Similar to our previous observations, the activity of pro-MMP-2 was reduced in the conditioned media from ING1a overexpressing HMF3s cells in comparison to control and GFP expressing cells.
ING1a overexpressing HMF3s cells induce disorganization of breast cancer cell derived organoids
In a physiological setting, cancer associated fibroblasts in the stroma are believed to release factors that help tumor cells to invade surrounding tissue, metastasize or divide more rapidly. In order to recapitulate this physiological phenomenon in vitro we employed a three dimensional culture system in which cells from an ER+ breast cancer cell line MCF7, and HMF3s fibroblast cells expressing ING1a, were grown separately in the context of matrix support to provide an environment that more closely reflects an in vivo setting. We then co-cultured MCF7 and HMF3s expressing ING1a in order to test whether paracrine factors released by HMF3s upon ING1a overexpression could affect organoids formed by MCF7.
Three dimensional culture assays allow phenotypic discrimination between nonmalignant and malignant mammary cells. Nonmalignant cells grown in a three dimensional context form growth arrested acinus-like colonies, whereas malignant cells form disorganized colonies that continue to proliferate . Similar results were obtained when HMF3s cells overexpressing ING1a were co-cultured with MCF7 cells (Fig. 5e ). The colonies formed in this combination were more disorganized and distorted as compared to individual controls and when MCF7 cells were co-cultured with GFP-expressing HMF3s cells (Fig. 5a, panel d, Additional file 1: Figure S1).
To test if the aggressive colonies formed were due to higher amounts of secreted MMPs upon ING1a overexpression in HMF3s cells, we next examined the morphology of MCF7 cells supplemented with conditioned media from HMF3s treated with the broad specificity MMP inhibitor GM6001. MCF7 cells supplemented with conditioned media from ING1a expressing HMF3s cells show a clear change in morphology (Fig. 5b panel b) in line with our previous observations. This phenotype was largely reversed when cells were supplemented with media from ING1a expressing HMF3s cells treated with GM6001 (Fig. 5b panel e). Cells looked more fusiform compared to cells treated with ING1a conditioned media in the absence of the inhibitor.
Taken together, these data suggest that ING1a expression in mesenchymal fibroblasts induces release of certain paracrine factors, which further induce epithelial breast cancer cells to attain a more aggressive phenotype.
In this study we investigated the significance of ING1 expression in the stromal region of breast cancer patients and tested the prognostic/predictive value of stromal ING1 as a prognostic factor in the Calgary Tamoxifen Cohort. Prognostic markers are associated with outcomes independent from therapy whereas, predictive markers predict outcome in terms of survival of a specific therapy. Considering the fact that the patients in the cohort studied were treated with tamoxifen irrespective of the ER status, ING1 acting as a predictive or prognostic marker remains unclear. Results show that stromal ING1 correlates with clinico-pathological characters like tumor grade (p = 0.001) and tumor size (p = 0.020) in the luminal (ER+/HER2-) breast cancer group consisting of 443 patients in the cohort. Specifically, low stromal ING1 expression was associated with tumor grade and size, i.e. patients with lower expression of stromal ING1 had better prognosis. This is an interesting observation and in contrast to what was observed in the case of tumor ING1 expression. Therefore, it appears that high ING1 levels in tumor and low ING1 levels in stroma predict the best outcomes for patients.
We also investigated if stromal ING1 expression was associated with disease free survival and disease specific overall survival by analyzing survival outcomes using Kaplan Meier curves. Significant association with 5 year DFS were observed in both the luminal group (p = 0.0001) and in the total population (p = 0.0001) of the cohort, with patients expressing low stromal ING1 having a better prognosis than patients with high stromal ING1. Similar results were obtained when the association with 7 year DSOS was analyzed, with both the luminal group (p = 0.0076) and total population (p = 0.110) showing better prognosis than the low stromal ING1 category, although the relationship was less statistically significant. Patients from the non-luminal category were also analyzed for similar associations, but no significant results were obtained for DFS or DSOS, suggesting that ING1 expression in different compartments of tissue (tumor/stroma) may have different roles to play in promoting or inhibiting the development of different sub-types of breast cancers.
Furthermore, multivariate analysis using Cox proportional hazards regression to adjust for important clinical covariates, confirmed that stromal ING1 expression was independently associated with DSS in breast cancer. When taking the total population of the cohort into account, stromal ING1 (HR 2.125, p = 0.004) not only came out to be an independent prognostic marker for breast cancer, but had better predictive power than already established biomarkers like HER2, ER and tumor size, which are commonly used in the clinic. When the luminal only group was analyzed, similar results were obtained, where stromal ING1 (HR 2.32, p = 0.002) came out as an independent prognostic marker in the cohort tested. In this particular population, stromal ING1 had better predictive value than tumor size, which is a clinically used biomarker. These results indicate that stromal ING1 is not only associated with patient survival and clinico-pathological characters like tumor grade and size in breast cancer, but could also be developed into a biomarker for breast cancer considering its predictive value than currently used clinical biomarkers. Further testing needs to be done in this regard by validating the present observation in a different breast cancer cohort, along with clinical testing, to establish stromal ING1 as a bona fide biomarker in breast cancer.
As this observation of association of stromal ING1 with patient survival was unanticipated for a typical type-II tumor suppressor, we wanted to determine the underlying reason for association of higher stromal ING1 expression with poor prognosis of patients in the luminal group of the cohort. Tumor cells in a patient are surrounded by a complex microenvironment that includes the extracellular matrix, diffusible growth factors and cytokines, and a variety of non-epithelial cells like endothelial cells, pericytes, smooth muscle cells, immune cells and fibroblasts collectively called as stroma. The concept of growth regulatory interactions between the stroma and adjacent epithelial cell population was first introduced by Schor et al. [37, 38]. This interaction is mediated by soluble autocrine/paracrine factors secreted from stromal cells that induce physiological changes such as increased proliferation, migration etc. in the adjacent epithelia. Specifically, fibroblasts present in the stroma are known to produce several families of growth factors that are key mediators of stroma-tumor cell interactions. Since fibroblasts constitute the majority of the stromal cells within a breast carcinoma, we used a human mammary fibroblast cell line to examine changes in cytokines and growth factors produced by these cells upon modulating levels of ING1. One previous study reported a role for the ING4 member of the ING family in regulating the secretory phenotype of primary fibroblasts , which is interesting in light of the fact that the different ING family members are stoichometric members of both histone deacetylase (HDAC, INGs 1&2) and histone acetyltransferase (HAT, INGs 3,4,5) complexes, and they appear to have overlapping function in regulating the secretome.
Since ING1b induced cell death in HMF3s cells, we used ING1a, which is known to induce senescence  in our experiments to determine the cytokine profile of these cells. Various studies have provided evidence that senescent human fibroblasts can promote the proliferation of pre-malignant and malignant epithelial cells in culture, and the formation of tumors in mice [32, 40, 41]. This is likely due to the fact that senescent fibroblasts show a senescence-associated secretory phenotype (SASP), which is similar to the paracrine growth factors and cytokines made in tumors that can contribute to cancer progression. Contrary to our expectations, our results showed that there was a significant decrease in the number of pro-inflammatory and proliferative cytokines such as IL-6, IL-8, PDGFA, PDGFB, VEGF and GRO in HMF3s cells upon ING1a overexpression. Chemotactic cytokines promoting growth and recruitment of immune cells (neutrophils, monocytes and macrophage) like Eotaxin, Fractalkine and MCP-3 were also released at lower amounts compared to controls. However, IL-15 and IP-10 which are known to have anti-apoptotic and anti-angiogenic properties [42, 43] also had lower levels upon ING1a expression in HMF3s cells, suggesting that these pathways may be activated by senescing fibroblasts.
Apart from the majority of cytokines and chemokines having reduced levels, some cytokines were increased upon ING1a expression. An increase in the levels of immune cell (granulocyte, monocyte and macrophage) promoting cytokines such as G-CSF, GM-CSF and MIP-1a was also observed along with increases in chemotactic and pro-inflammatory cytokine MCP-1.
In contrast to the ING1a effects on cytokines and chemokines, a much more directed effect was seen for matrix metalloproteases. Stromal cells secrete matrix metalloproteases such as MMP-1, 2, 3, 9 and 10, all of which can promote epithelial transformation  and are known to have pro-angiogenic and metastatic properties [45, 46]. Previous studies have shown that senescent cells secrete increased levels of MMPs and the MMP family members that are consistently upregulated in fibroblasts undergoing senescence are MMP-1, 3 and 10 . Our previous study shows that ING1a induces senescence suggesting that these MMPs may contribute to epithelial cell transformation. Significant increases in the levels of MMPs implicated in senescence upon ING1a overexpression in HMF3s cells also indicates senescence induction in these cells. A reciprocal effect was observed in the case of inhibitors of MMPs (TIMPs) as the levels of TIMP-2, 3 and 4 showed a significant decrease in ING1a expressing cells indicating that both MMP production increased and inhibitor of MMP activity had decreased in a coordinated manner in these cells.
These results clearly showed an increased amount of MMPs being secreted by the HMF3s cells expressing ING1a. To test if the MMPs secreted were active, we performed zymography with specific substrates for MMP-1 and MMP-2 to analyze their enzymatic activity in vitro. Activities on the zymogram corresponding to levels of MMP-1 and 2 previously observed were obtained confirming that the MMPs secreted by ING1a expressing HMF3s cells were biologically active.
Next, in order to functionally investigate whether soluble factors produced by fibroblasts upon ING1a expression are able to induce changes in tumor cells, we co-cultured HMF3s cells and MCF7 cells and studied their behavior in three dimensional cultures. The organoids formed when HMF3s cells expressing ING1a were co-cultured with MCF7 cells were highly disorganized as compared to GFP expressing co-cultured cells. This is an indication that the MMPs and cytokines secreted by ING1a expressing cells were able to induce morphological changes in the cancer cells resulting in disorganized and more aggressive colonies. Partial reversal of morphology of MCF7 cells when supplemented with conditioned media from ING1a and MMP inhibitor treated cells in comparison to MCF7 cells treated with ING1a only media, further indicates that MMPs play a role in MCF7 cells attaining a more aggressive phenotype in response to altered levels of ING1. The ability of ING1a expressing fibroblasts to stimulate the invasion of tumor cells into the matrix indicated that secreted factors produced by these cells in response to ING1a expression may be sufficient to induce invasiveness in these cells. This may explain the phenomenon believed to occur in tumor-stroma interactions in cancer patients, where senescent cancer associated fibroblasts release soluble factors which provides an environment that helps the tumors to grow more aggressively and to metastasize to form secondary tumors.
Overall, these results from the cytokine and MMP profiling and the functional assays provide a possible explanation for the poor survival of breast cancer patients having elevated levels of ING1 in tumor associated stroma as observed in the AQUA analysis of patients having luminal types of breast cancer in the cohort we tested. Both major isoforms of ING1, ING1a and ING1b have been reported to induce senescence in cells upon overexpression [22, 47, 48] although ING1b also induces apoptosis at higher levels while ING1a appears to solely affect senescence. Therefore, we speculate that increased levels of ING1 in the stroma may induce senescence which promotes stromal cells developing a senescence associated secretory phenotype, releasing paracrine and cytokine growth factors and MMPs. This would result in more aggressive tumor formation in such patients leading to their documented poor survival.
Presently, a high incidence of breast cancer is observed in women worldwide. This is most likely due to the availability of widespread screening programs used to detect breast cancer, which otherwise may never get diagnosed. There is an inverse relation between the cost of treatment and patient survival as the breast cancer progresses to higher grades which makes screening and diagnosing cancers at earlier stages important, improving patient survival. Our study here provides substantial evidence for establishing ING1 as a probable biomarker for breast cancer. We have shown in this study that ING1 can specifically predict the survival of patients with luminal type breast cancer. Specifically, higher ING1 expression in the stroma leads to poor survival of patients with luminal type breast cancer due to increase in MMP production, which may in turn allow cancer cells to escape and form secondary metastasis. Higher stromal ING1 also establishes a pro-tumor survival niche by virtue of the cytokines and chemokines released by the stromal cells. This phenomenon although anomalous to a typical tumor suppressor, defines a unique role of ING1 in breast cancer pathogenesis. Overall, this study provides important pre-clinical information that may be helpful to evaluate the potential usefulness of the ING family of tumor suppressors in breast cancer prognosis and treatment.
Immortalized human mammary fibroblasts HMF3s (a kind gift from Dr. Parmjit Jat) and MCF7 cells were cultured in H-DMEM (Lonza) supplemented with 10 % FBS, 0.1 mg/ml streptomycin and 100 U/ml penicillin and maintained in a humidified atmosphere of 5 % CO2 and 95 % air at 37 °C. Cells were routinely tested for mycoplasma contamination. For MMP inhibitor assays, HMF3s cells were treated with 10 μM GM6001 (Millipore) MMP inhibitor alone or in combination with 15 MOI Ad-ING1a or Ad-GFP. Media were collected after 48 h and stored at -80 °C till further use. MCF 7 cells supplemented with conditioned media from these cells were analyzed for changes in morphology after 24 h using a Zeiss Axiovert 200 M microscope.
Multiplex assay for cytokine and chemokine screening
Media from transfected/infected cells were collected and screened for released cytokines and chemokines using an ELISA based assay (Eve Technologies, Calgary Alberta). Cells (HMF3s) were inoculated overnight in 6 well dishes and were infected with Ad-ING1a or Ad-GFP virus at 15 MOI and allowed to grow for 48 h with media changed 12 h post infection. After 48 h, cell media were carefully collected in sterile centrifuge tubes without disturbing the cells. The media were then centrifuged at 4 °C for 10 min at 13,000 rpm. After centrifugation, the media supernatant were transferred into fresh sterile tubes and stored at −80 °C unless analyzed immediately.
Three-dimensional cell culture
Three-dimensional culture of HMF3s and MCF7 cells were performed in ultra-low attachment 96-well plates (BD Biosciences). HMF3s cells were infected with Ad-ING1a or Ad-GFP at 15 MOI for 48 h. The plates were firstly coated with 50 μl of 30 % growth factor reduced Matrigel (3 mg/ml) (BD Bioscience) in complete medium (DMEM-containing 10 % FEBS, penicillin, streptomycin and amphotericin B (Lonza) and were incubated for 1 h in a CO2 incubator at 37 °C to form a layer. Cell suspensions of HMF3s and MCF7 cells were then made (100 cells/50 μl) in 30 % Matrigel and were carefully layered without formation of bubbles on the solidified layer in the wells. For co-culture experiments, a 1:1 ratio of HMF3s cells and MCF7 cells was used. Fresh media were supplemented every three days and images were taken after 2 weeks using a Zeiss Axiovert 200 M microscope.
To determine the activity of matrix metalloproteases MMP-1 and MMP-2, gelatin and casein zymography were performed, respectively. Briefly, HMF3s cells were grown in 6 well dishes and infected with Ad-ING1a or Ad-GFP for 48 h at 15 MOI and the media was centrifuged at 4 °C for 10 min at 13,000 rpm. The collected media supernatants were then mixed with 2X sample buffer (65.8 mM Tris-HCl pH 6.8, 25 % (w/v) glycerol, 2 % SDS, 0.1 % bromophenol blue) and incubated at room temperature for 10-15 min. The samples were then subjected to zymography by resolving on 10 % SDS- polyacrylamide gels containing 1 mg/ml porcine skin-derived gelatin (Sigma) or casein (Sigma). After electrophoresis, the gels were incubated for 30 min at room temperature with gentle agitation in renaturation buffer (2.5 % Triton X-100) to remove SDS. The gels were then incubated in developing buffer (50 mM Tris-HCl, 0.2 M NaCl, 5 mM CaCl2 and 0.02 % Brij 35) at 37 °C overnight with gentle agitation. After incubation in the developing buffer, gels were stained with 0.5 % (w/v) Coomassie Blue R-250 for 30 min and destained with destaining solution methanol : acetic acid : water (50:10:40). For casein zymography, gels were pre-run for 30 min at 100 V before loading samples to remove excess casein.
Patient cohort and ethics
The Calgary Tamoxifen Cohort which contains a demographic, clinical and pathology data for 819 breast cancer patients diagnosed between 1985 and 2000 at the Tom Baker Cancer Centre in Calgary, Canada was used in this study. Inclusion and exclusion criteria and detailed description of the cohort have been described previously . This study involving the Tamoxifen cohort was ethically approved (Ethics ID E-17422) by the Conjoint Health Research Ethics Board (CHREB) at the University of Calgary, Canada.
Fluorescence immunohistochemistry and automated image acquisition
Fluorescence immunohistochemistry and image acquisition of the patient samples was performed as described previously . Briefly, 4 μm thick sections were cut from the TMA block and after deparaffinization, were rinsed in ethanol, and rehydrated. Heat-induced epitope retrieval was performed in a decloaking chamber (Biocare Medical, Concord, CA, USA), and slides were stained using a Dako Autostainer. Automated image acquisition was performed using AQUAnalysis® program as described previously . CAb 5 antibody specific to ING1 that can recognize both ING1a and ING1b was used for analyzing ING1 levels in patient samples.
Assessment of ING1 expression
The average intensity of target ING1 signal in the stromal mask was tabulated and used to generate stromal specific AQUA scores, which reflect the average signal intensity in the stromal area of the tissue sample. The ING1 expression score was defined as the mean ING1 AQUA score from triplicate cores for each patient sample. Patients were dichotomized at the lowest or highest tertiles of ING1 expression within the entire cohort, to define Low ING1 and High ING1 categories.
Statistical analysis for patient data
Statistical analyses were performed using Stata 12 (StataCorp LP). For survival analysis, disease free survival (DFS) which is defined as the time of diagnosis to recurrence, metastatic disease, or death from breast cancer and disease specific overall survival (DSOS), which is the time of diagnosis to death from breast cancer were analyzed. Patients were censored at the time a patient died from another cause, or the follow-up period ended. Kaplan Meier survival analysis was performed to estimate the probability of 5-year DFS or 7-year DSOS. Cox proportional hazards analyses were conducted to assess the impact of clinical covariates in multivariate analysis.
We thank Elizabeth Kornaga, Brant Pohorelic, Michelle Dean and Mei Konno from the FTIU, Tom Baker Cancer Center, for help with tissue microarray staining and data collection. We also acknowledge Donna Boland from the SACRI Antibody Facility for ING1 antibody production and purification and Dr. Shoraf Dadakhujaev for his help with 3D cultures. This study was supported by grants from the Canadian Breast Cancer Foundation (http://www.cbcf.org/prairies/Pages/default.aspx), the Canadian Institutes of Health Research, grant number MOP-133646 (http://www.cihr-irsc.gc.ca/e/193.html) and Alberta Innovates–Health Solutions (http://www.aihealthsolutions.ca/) to KR.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010;316(8):1324–31. Epub 2010/03/10.View ArticlePubMedGoogle Scholar
- Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res. 2009;69(1):369–78. Epub 2009/01/02.PubMed CentralView ArticlePubMedGoogle Scholar
- Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB, et al. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A. 1987;84(16):5763–7. Epub 1987/08/01.PubMed CentralView ArticlePubMedGoogle Scholar
- Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010;70(17):6945–56. Epub 2010/08/12.View ArticlePubMedGoogle Scholar
- Lohr F, Lo DY, Zaharoff DA, Hu K, Zhang X, Li Y, et al. Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res. 2001;61(8):3281–4. Epub 2001/04/20.PubMedGoogle Scholar
- Shao ZM, Nguyen M, Barsky SH. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene. 2000;19(38):4337–45. Epub 2000/09/12.View ArticlePubMedGoogle Scholar
- Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332–7. Epub 2004/11/19.PubMed CentralView ArticlePubMedGoogle Scholar
- Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303(5659):848–51. Epub 2004/02/07.View ArticlePubMedGoogle Scholar
- Ku NO, Toivola DM, Strnad P, Omary MB. Cytoskeletal keratin glycosylation protects epithelial tissue from injury. Nat Cell Biol. 2010;12(9):876–85. Epub 2010/08/24.PubMed CentralView ArticlePubMedGoogle Scholar
- Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891–906. Epub 2009/11/26.PubMed CentralView ArticlePubMedGoogle Scholar
- Gerber PA, Hippe A, Buhren BA, Muller A, Homey B. Chemokines in tumor-associated angiogenesis. Biol Chem. 2009;390(12):1213–23. Epub 2009/10/07.View ArticlePubMedGoogle Scholar
- Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, et al. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer J Int Du cancer. 2009;124(4):853–61. Epub 2008/11/28.View ArticleGoogle Scholar
- Lederle W, Hartenstein B, Meides A, Kunzelmann H, Werb Z, Angel P, et al. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis. 2010;31(7):1175–84. Epub 2009/11/07.PubMed CentralView ArticlePubMedGoogle Scholar
- Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27(31):5287–97. Epub 2009/09/10.PubMed CentralView ArticlePubMedGoogle Scholar
- McMillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov. 2013;12(3):217–28. Epub 2013/03/02.View ArticlePubMedGoogle Scholar
- Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012;31(1-2):195–208. Epub 2011/11/22.View ArticlePubMedGoogle Scholar
- Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010;29(2):273–83. Epub 2010/04/15.PubMed CentralView ArticlePubMedGoogle Scholar
- Guerillon C, Bigot N, Pedeux R. The ING tumor suppressor genes: status in human tumors. Cancer Lett. 2014;345(1):1–16. Epub 2013/12/18.View ArticlePubMedGoogle Scholar
- He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol. 2005;22(1):104–16. Epub 2004/09/10.View ArticlePubMedGoogle Scholar
- Vieyra D, Toyama T, Hara Y, Boland D, Johnston R, Riabowol K. ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Res. 2002;62(15):4445–52. Epub 2002/08/03.PubMedGoogle Scholar
- Guerillon C, Larrieu D, Pedeux R. ING1 and ING2: multifaceted tumor suppressor genes. Cell Mol Life Sci. 2013;70(20):3753–72. Epub 2013/02/16.View ArticlePubMedGoogle Scholar
- Soliman MA, Berardi P, Pastyryeva S, Bonnefin P, Feng X, Colina A, et al. ING1a expression increases during replicative senescence and induces a senescent phenotype. Aging cell. 2008;7(6):783–94. Epub 2008/08/12.View ArticlePubMedGoogle Scholar
- Helbing CC, Veillette C, Riabowol K, Johnston RN, Garkavtsev I. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res. 1997;57(7):1255–8. Epub 1997/04/01.PubMedGoogle Scholar
- Feng X, Hara Y, Riabowol K. Different HATS of the ING1 gene family. Trends Cell Biol. 2002;12(11):532–8. Epub 2002/11/26.View ArticlePubMedGoogle Scholar
- Garkavtsev I, Kazarov A, Gudkov A, Riabowol K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet. 1996;14(4):415–20. Epub 1996/12/01.View ArticlePubMedGoogle Scholar
- Gong W, Suzuki K, Russell M, Riabowol K. Function of the ING family of PHD proteins in cancer. Int J Biochem Cell Biol. 2005;37(5):1054–65. Epub 2005/03/04.View ArticlePubMedGoogle Scholar
- Tallen G, Riabowol K, Wolff JE. Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells. Anticancer Res. 2003;23(2B):1631–5. Epub 2003/06/25.PubMedGoogle Scholar
- Vieyra D, Senger DL, Toyama T, Muzik H, Brasher PM, Johnston RN, et al. Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors. Clin Cancer Res. 2003;9(16 Pt 1):5952–61. Epub 2003/12/17.PubMedGoogle Scholar
- Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, et al. Negative regulation of NF-kappaB by the ING4 tumor suppressor in breast cancer. PLoS One. 2012;7(10), e46823. Epub 2012/10/12.PubMed CentralView ArticlePubMedGoogle Scholar
- Kim S, Welm AL, Bishop JM. A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Res. 2010;70(12):5155–62. Epub 2010/05/27.PubMed CentralView ArticlePubMedGoogle Scholar
- Thakur S, Singla AK, Chen J, Tran U, Yang Y, Salazar C, et al. Reduced ING1 levels in breast cancer promotes metastasis. Oncotarget. 2014;5(12):4244–56. Epub 2014/06/26.PubMed CentralPubMedGoogle Scholar
- Olsen CJ, Moreira J, Lukanidin EM, Ambartsumian NS. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts. BMC Cancer. 2010;10:444. Epub 2010/08/21.PubMed CentralView ArticlePubMedGoogle Scholar
- Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436(7050):518–24. Epub 2005/07/29.PubMed CentralView ArticlePubMedGoogle Scholar
- Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120(3):303–13. Epub 2005/02/15.View ArticlePubMedGoogle Scholar
- Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 2005;5(9):675–88. Epub 2005/09/09.View ArticlePubMedGoogle Scholar
- Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A. 1992;89(19):9064–8. Epub 1992/10/01.PubMed CentralView ArticlePubMedGoogle Scholar
- Schor SL, Schor AM, Durning P, Rushton G. Skin fibroblasts obtained from cancer patients display foetal-like migratory behaviour on collagen gels. J Cell Sci. 1985;73:235–44. Epub 1985/02/01.PubMedGoogle Scholar
- Schor SL, Schor AM, Rushton G, Smith L. Adult, foetal and transformed fibroblasts display different migratory phenotypes on collagen gels: evidence for an isoformic transition during foetal development. J Cell Sci. 1985;73:221–34. Epub 1985/02/01.PubMedGoogle Scholar
- Moreno A, Soleto I, Garcia-Sanz P, Moreno-Bueno G, Palmero I. ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth. Oncogene. 2014;33(15):1945–53. Epub 2013/04/23.View ArticlePubMedGoogle Scholar
- Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A. 2001;98(21):12072–7. Epub 2001/10/11.PubMed CentralView ArticlePubMedGoogle Scholar
- Parrinello S, Coppe JP, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005;118(Pt 3):485–96. Epub 2005/01/20.View ArticlePubMedGoogle Scholar
- Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 1995;182(1):155–62. Epub 1995/07/01.View ArticlePubMedGoogle Scholar
- Malamut G, El Machhour R, Montcuquet N, Martin-Lanneree S, Dusanter-Fourt I, Verkarre V, et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest. 2010;120(6):2131–43. Epub 2010/05/05.PubMed CentralView ArticlePubMedGoogle Scholar
- Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation. 2002;70(9-10):561–73. Epub 2002/12/21.View ArticlePubMedGoogle Scholar
- Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998;58(5):1048–51. Epub 1998/03/21.PubMedGoogle Scholar
- Liu D, Hornsby PJ. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res. 2007;67(7):3117–26. Epub 2007/04/06.View ArticlePubMedGoogle Scholar
- Abad M, Moreno A, Palacios A, Narita M, Blanco F, Moreno-Bueno G, et al. The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. Aging cell. 2011;10(1):158–71. Epub 2010/11/17.View ArticlePubMedGoogle Scholar
- Li N, Li Q, Cao X, Zhao G, Xue L, Tong T. The tumor suppressor p33ING1b upregulates p16INK4a expression and induces cellular senescence. FEBS Lett. 2011;585(19):3106–12. Epub 2011/09/08.View ArticlePubMedGoogle Scholar